Evusheld long - acting antibody combination retains neutralising activity against Omicron variant in independent FDA study

AstraZeneca’s antibody against a strain of Covid-19 which was previously linked to the Wuhan variant of the virus retained neutralising activity, according to an independent US Food and Drug Administration (FDA) study published in the journal The Lancet.

Source: pharmiweb.com
Published on 2021-12-21

Related news